Susceptibility of ClinicalMycobacterium tuberculosisIsolates to a Potentially Less Toxic Derivate of Linezolid, PNU-100480

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

(2010) Robert S. Wallis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients

(2010) Jan-Willem C. Alffenaar et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetics and Whole‐Blood Bactericidal Activity againstMycobacterium tuberculosisof Single Doses of PNU‐100480 in Healthy Volunteers

(2010) Robert S. Wallis et al.   JOURNAL OF INFECTIOUS DISEASES

Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis

(2009) Kathy N. Williams et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

(2009) G. B. Migliori et al.   EUROPEAN RESPIRATORY JOURNAL

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response

(2009) W.-J. Koh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

(2008) K. N. Williams et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

(2008) Hae-Seong Nam et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS